Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds. 2015

Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
Department of Biochemistry, Faculty of Science, P. J. Šafárik University in Košice, Moyzesova 11, 040 01 Košice, Slovak Republic.

HL-60 cancer cells were treated with a series of novel acridine derivatives (derivatives 1-4) in order to test the compounds' ability to inhibit both cancer cell growth and topoisomerase I and II activity. Binding studies of derivatives 1-4 with calf thymus DNA were also performed using a number of techniques (UV-Vis and fluorescence spectroscopy, thermal denaturation, linear dichroism and viscometry) to determine the nature of the interaction between the compounds and ctDNA. The binding constants for the complexes of the studied acridine derivatives with DNA were calculated from UV-Vis spectroscopic titrations (K=3.1×10(4)-2.0×10(3)M(-1)). Some of the compounds showed a strong inhibitory effect against Topo II at the relatively low concentration of 5μM. Topo I/II inhibition mode assays were also performed and verified that the novel compounds are topoisomerase suppressors rather than poisons. The biological activities of derivatives were studied using MTT assay and flow cytometric methods (detection of mitochondrial membrane potential, measurement of cell viability) after 24 and 48h incubation. The ability of derivatives to impair cell proliferation was tested by an analysis of cell cycle distribution.

UI MeSH Term Description Entries
D009690 Nucleic Acid Conformation The spatial arrangement of the atoms of a nucleic acid or polynucleotide that results in its characteristic 3-dimensional shape. DNA Conformation,RNA Conformation,Conformation, DNA,Conformation, Nucleic Acid,Conformation, RNA,Conformations, DNA,Conformations, Nucleic Acid,Conformations, RNA,DNA Conformations,Nucleic Acid Conformations,RNA Conformations
D009691 Nucleic Acid Denaturation Disruption of the secondary structure of nucleic acids by heat, extreme pH or chemical treatment. Double strand DNA is "melted" by dissociation of the non-covalent hydrogen bonds and hydrophobic interactions. Denatured DNA appears to be a single-stranded flexible structure. The effects of denaturation on RNA are similar though less pronounced and largely reversible. DNA Denaturation,DNA Melting,RNA Denaturation,Acid Denaturation, Nucleic,Denaturation, DNA,Denaturation, Nucleic Acid,Denaturation, RNA,Nucleic Acid Denaturations
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004264 DNA Topoisomerases, Type I DNA TOPOISOMERASES that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. DNA Topoisomerases, Type I enzymes reduce the topological stress in the DNA structure by relaxing the superhelical turns and knotted rings in the DNA helix. DNA Nicking-Closing Protein,DNA Relaxing Enzyme,DNA Relaxing Protein,DNA Topoisomerase,DNA Topoisomerase I,DNA Topoisomerase III,DNA Topoisomerase III alpha,DNA Topoisomerase III beta,DNA Untwisting Enzyme,DNA Untwisting Protein,TOP3 Topoisomerase,TOP3alpha,TOPO IIIalpha,Topo III,Topoisomerase III,Topoisomerase III beta,Topoisomerase IIIalpha,Topoisomerase IIIbeta,DNA Nicking-Closing Proteins,DNA Relaxing Enzymes,DNA Type 1 Topoisomerase,DNA Untwisting Enzymes,DNA Untwisting Proteins,Topoisomerase I,Type I DNA Topoisomerase,III beta, Topoisomerase,III, DNA Topoisomerase,III, Topo,III, Topoisomerase,IIIalpha, TOPO,IIIalpha, Topoisomerase,IIIbeta, Topoisomerase,Topoisomerase III, DNA,Topoisomerase, TOP3,beta, Topoisomerase III
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
September 2012, Archives of pharmacal research,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
June 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
July 2006, Biological & pharmaceutical bulletin,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
September 1994, Leukemia & lymphoma,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
September 2010, Archives of pharmacal research,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
August 2003, Biochemical pharmacology,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
October 2009, Archives of pharmacal research,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
January 2005, Oncology research,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
January 2001, Chemical research in toxicology,
Jana Janočková, and Jana Plšíková, and Jana Kašpárková, and Viktor Brabec, and Rastislav Jendželovský, and Jaromír Mikeš, and Ján Kovaľ, and Slávka Hamuľaková, and Peter Fedoročko, and Kamil Kuča, and Mária Kožurková
March 1993, Blood,
Copied contents to your clipboard!